Based on these data, tepotinib was granted breakthrough therapy designation by the FDA in September 2019 for the treatment of metastatic NSCLC patients with MET exon 14 skipping mutations who progressed following platinum-based cancer therapy (Figure 2). The gene discussed is MET; the disease is non-small cell lung carcinoma.